Sector News

Novartis’s Alcon eye-care unit to enter Swiss index after spin off

February 6, 2019
Life sciences

Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland’s 20 largest listed companies, market operator SIX said on Tuesday.

Information about any other changes to SMI and Switzerland’s other indexes will be released later, the bourse said.

Novartis last year announced the spin off of Alcon to the Basel drugmaker’s shareholders in the first half of this year.

Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.

By John Revill

Source: Reuters

Related News

June 4, 2020

Accent, AstraZeneca take aim at RNA modifiers in $55M cancer pact

Life sciences

Since it launched in 2018, Accent Therapeutics has busied itself discovering new targets for cancer drugs in the space of RNA-modifying proteins. But the time for lying low is over—just […]

June 4, 2020

FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumab

Life sciences

Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was […]

June 2, 2020

New vaccine for Ebola among CHMP recommendations

Life sciences

Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting. […]